Genmab — December 2025
-
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting https://proinvestor.com/investornyt/1392313/genmab-to-hold-2025-rampd-update-and-ash-data-review-meeting
-
According to GlobalData’s analyst consensus forecast, global sales of Epkinly are projected to reach $2.6bn by 2031, and this new second-line FL indication is expected to significantly expand its sales. In comparison, Lunsumio, Ordspono, and Monjuvi are expected to reach global sales of approximately $920m, $336m, and $521m, respectively, by 2031. https://www.clinicaltrialsarena.com/analyst-comment/ash-2025-abbvie-genmab-epkinly-new-standard-second-line-fl/
-
Ugevideo: Zealand Pharma, Genmab, Bavarian, Nanexa & Novo https://proinvestor.com/boards/130256
-
Jeg er helt enig med Helge dette spørgsmål. Hvis denne chat kun handlede om aktiers udvikling på den helt korte bane, kunne jeg forstå dig Raun. Historisk har man klogeligt haft de lange briller på når det handler om Genmab, og selv har jeg derudover nydt endog særdeles godt af Bull i forbindelse med disse tilbagefald. Rigtig godt! Den har som oftest været lige så let at læse som en åben bog. Men indrømmet - ikke altid i den seneste tid.
-
Jeg mener at Genmab, især når det angår grundlæggende produktfremgang og udvikling, i den grad er på den rette vej. Tager man udgangspunkt deri, kommer vi til at se væsentligt højere kurser. Men også TA mæssigt peger pilen - i den grad - opad. Pyt med tilbagefaldene. Den er steget mere end 50% fra bunden, og der kommer mere. Traderne nyder lige nu godt af, at det ikke er alle der har ro i maven, som f.eks undertegnede.
-
-
Tak Peter.
-
Genmab gennemfører køb af hollandsk biotekselskab https://proinvestor.com/investornyt/1392828/genmab-gennemforer-kob-af-hollandsk-biotekselskab
-
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period https://ir.genmab.com/news-releases/news-release-details/genmab-announces-completion-tender-offer-outstanding-common
-
some ASH news also for Hemab on Sutacimig / HMB-001 - Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study https://www.hemab.com/news-items/hemab-therapeutics-announces-positive-complete-phase-2-data-for-sutacimig-in-glanzmann-thrombasthenia-at-ash-2025-plans-to-advance-to-pivotal-phase-3-study
-
and 2 oral presentations on Mim8 via https://sciencehub.novonordisk.com/congresses/ash2025.html
heldigvis vendte genmab rundt igår og helt som forventet fortsætter TA opturen - vurdere der er TA brændstof til midt i Januar men med volatilitet undervejs - target ca. 2200
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind